Cargando…

Epstein-Barr virus lytic gene expression is tightly linked to ER stress but not cytotoxicity with bortezomib or nelfinavir

Detalles Bibliográficos
Autores principales:	Shirley, Courtney M, Kalu, Nene, Shamay, Meir, Ambinder, Richard F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330051/ http://dx.doi.org/10.1186/1750-9378-7-S1-P32

Ejemplares similares

C/EBPbeta mediates bortezomib-induced EBV and KSHV lytic gene expression
por: O’Farrell, Courtney, et al.
Publicado: (2010)

ER stress activates lytic gene expression in KSHV-associated tumor cell lines
por: Kalu, Nene, et al.
Publicado: (2012)

CpG methylation as a tool to characterize cell-free Epstein-Barr virus DNA
por: Shamay, Meir, et al.
Publicado: (2012)

Burkitt's lymphoma: differential killing of Epstein-Barr virus (EBV) (+) and EBV(-) Burkitt lymphoma cells in vitro and dose-dependent lytic induction by bortezomib in vivo
por: Dufresne, AL, et al.
Publicado: (2009)

The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma
por: Besse, Lenka, et al.
Publicado: (2023)

Arsenicals, the Integrated Stress Response, and Epstein–Barr Virus Lytic Gene Expression
por: Lee, Jaeyeun, et al.
Publicado: (2021)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Parthenolide induces apoptosis and lytic cytotoxicity in Epstein-Barr virus-positive Burkitt lymphoma
por: LI, YUAN, et al.
Publicado: (2012)

Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells
por: Kawabata, S, et al.
Publicado: (2012)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus
por: Gorres, Kelly L., et al.
Publicado: (2016)

Inhibitory Effects of Resveratrol on the Epstein-Barr Virus Lytic Cycle
por: Yiu, Ching-Yi, et al.
Publicado: (2010)

Functional Implications of Epstein-Barr Virus Lytic Genes in Carcinogenesis
por: Yap, Lee Fah, et al.
Publicado: (2022)

Epstein–Barr Virus: How Its Lytic Phase Contributes to Oncogenesis
por: Rosemarie, Quincy, et al.
Publicado: (2020)

Molecular Basis of Epstein–Barr Virus Latency Establishment and Lytic Reactivation
por: Murata, Takayuki, et al.
Publicado: (2021)

Rta is the principal activator of Epstein-Barr virus epithelial lytic transcription
por: Ali, Ahmed, et al.
Publicado: (2022)

Immediate Early and Early Lytic Cycle Proteins Are Frequent Targets of the Epstein-Barr Virus–induced Cytotoxic T Cell Response
por: Steven, N.M., et al.
Publicado: (1997)

Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation
por: Lee, Hyun Gyu, et al.
Publicado: (2015)

Activation of the Epstein–Barr virus lytic cycle by the latex of the plant Euphorbia tirucalli
por: MacNeil, A, et al.
Publicado: (2003)

ZEB1 Regulates the Latent-Lytic Switch in Infection by Epstein-Barr Virus
por: Yu, Xianming, et al.
Publicado: (2007)

Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis
por: Li, Hongde, et al.
Publicado: (2016)

Inhibition of Epstein-Barr Virus Lytic Reactivation by the Atypical Antipsychotic Drug Clozapine
por: Anderson, Abbie G., et al.
Publicado: (2019)

Replication Compartments—The Great Survival Strategy for Epstein–Barr Virus Lytic Replication
por: Sugimoto, Atsuko
Publicado: (2022)

Trichloromethane fraction of Incarvillea compacta induces lytic cytotoxicity and apoptosis in Epstein-Barr virus-positive gastric cancer AGS cells
por: Zhang, Lijing, et al.
Publicado: (2016)

Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells
por: Brüning, Ansgar, et al.
Publicado: (2010)

Complexities associated with expression of Epstein–Barr virus (EBV) lytic origins of DNA replication
por: Xue, Shao-An, et al.
Publicado: (2007)

Therapies based on targeting Epstein‐Barr virus lytic replication for EBV‐associated malignancies
por: Li, Hongde, et al.
Publicado: (2018)

A Temporal Proteomic Map of Epstein-Barr Virus Lytic Replication in B Cells
por: Ersing, Ina, et al.
Publicado: (2017)

Pseudouridylation of Epstein-Barr virus noncoding RNA EBER2 facilitates lytic replication
por: Henry, Belle A., et al.
Publicado: (2022)

Nelfinavir Inhibition of Kaposi’s sarcoma-associated herpesvirus protein expression and capsid assembly
por: Li, Maggie, et al.
Publicado: (2023)

The Dual Functions of Andrographolide in the Epstein–Barr Virus-Positive Head-and-Neck Cancer Cells: The Inhibition of Lytic Reactivation of the Epstein–Barr Virus and the Induction of Cell Death
por: Heawchaiyaphum, Chukkris, et al.
Publicado: (2023)

Autophagy-Dependent Reactivation of Epstein-Barr Virus Lytic Cycle and Combinatorial Effects of Autophagy-Dependent and Independent Lytic Inducers in Nasopharyngeal Carcinoma
por: Yiu, Stephanie Pei Tung, et al.
Publicado: (2019)

The FDA-Approved Drug Nelfinavir Inhibits Lytic Cell-Free but Not Cell-Associated Nonlytic Transmission of Human Adenovirus
por: Georgi, Fanny, et al.
Publicado: (2020)

Inhibition of Poly(ADP-ribose)polymerase impairs Epstein Barr Virus lytic cycle progression
por: Mattiussi, Stefania, et al.
Publicado: (2007)

MCAF1 and synergistic activation of the transcription of Epstein–Barr virus lytic genes by Rta and Zta
por: Chang, Li-Kwan, et al.
Publicado: (2010)

The Immunomodulatory Capacity of an Epstein-Barr Virus Abortive Lytic Cycle: Potential Contribution to Viral Tumorigenesis
por: Morales-Sánchez, Abigail, et al.
Publicado: (2018)

Bromodomain and extraterminal inhibitors block the Epstein-Barr virus lytic cycle at two distinct steps
por: Keck, Kristin M., et al.
Publicado: (2017)

PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter
por: Lupey-Green, Lena N., et al.
Publicado: (2017)

Lytic Induction Therapy against Epstein–Barr Virus-Associated Malignancies: Past, Present, and Future
por: Yiu, Stephanie Pei Tung, et al.
Publicado: (2020)

Subclinical Epstein-Barr Virus Primary Infection and Lytic Reactivation Induce Thyrotropin Receptor Autoantibodies
por: Tamoto, Naohiro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0pq1pkr92phj1ugjcth5sl6i53